Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
NCT04650724
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
3
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
T cell infusion agent targeting BCMA chimeric antigen receptor
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators
[object Object]